GlobeNewswire

Communique from annual general meeting in Velcora Holding AB

Dela

Annual General Meeting has been held in Velcora Holding AB, reg. no. 556830-4033, ("Velcora" or the "Company") and the shareholders e.g. made the following resolutions.

Adoption of profit and loss account and balance sheet
The meeting resolved to adopt the profit and loss account and balance sheet for the company and the group.

The meeting resolved to allocate the profit for the year in accordance with the board of directors' proposal, i.e. that the net loss of the year, SEK 15.5 million is carried forward into the next year.

The meeting resolved to discharge each board member (including deputy members) and the managing director from liability for their management of the Company's affairs during 2015.

The meeting resolved that for the fiscal year 2016 (1st Jan. - 31st Dec.) remuneration of SEK 210 000 excluding VAT (SEK 140 000 p.a. for 1st Jan - 30th Jun and SEK 280 000 p.a. for 1st Jul - 31st Dec) shall be paid to Peter Schmid, SEK 140 000 excluding VAT shall be paid to Lennart Sundén and SEK 70 000 excluding VAT (SEK 140 000 p.a. for 1st Jul -31st Dec) shall be paid to Björn Leidelöf, it is further proposed that no remuneration shall be paid to the remaining directors of the board. The remuneration to the auditor shall be paid in accordance with approved invoice.

The meeting re-elected Göran Wallenius, Lennart Sundén, Andreas Bruzelius and Ulrik Smith and elected Björn Leidelöf as directors and Peter Schmid as Chairman until the next annual general meeting. Christoffer Wallenius and Kristoffer Stensholt Feet were elected as deputy board members for the time until the end of the next annual general meeting.

The meeting re-elected KPMG AB with Håkan Olsson Reising as the auditor in charge as the Company's auditor until the next annual general meeting.

The meeting resolved unanimously to authorise the board for the time until the next annual meeting, from time to time, to decide on issues of shares and/or convertibles, entailing such an increase of the company's share capital and number of shares that can be made without changes to the company's articles of association. The issues shall be made in relation to corporate acquisitions and/or directed to newly appointed employees. Issues can, under consideration of the shareholder agreement, be carried out with or without preference for the company's shareholders and with payment in the form of cash and/or contribution in kind, set-off or otherwise with conditions. The authorisation includes all existing share classes.

Tumba i juni 2016
Velcora Holding AB
Styrelsen

For further information, visit www.velcora.se or contact;

Richard Tuck CEO
Velcora Holding AB (publ)
Box 120
14722 Tumba
Tel +46708784301
www.velcora.se
Richard.tuck@roplan.com




This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Velcora Holding AB via Globenewswire

HUG#2023954

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Aprea Therapeutics presents continued positive results from a Phase Ib/II study of APR 2462.12.2018 18:00Pressmeddelande

STOCKHOLM, December 2, 2018. Karolinska Development's portfolio company Aprea Therapeutics today presented positive clinical results for its drug candidate APR 246 at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego, US. An Overall Response Rate of 95% and a Complete Remission (CR) rate of 70% were achieved in an ongoing Phase I/II combination study of APR 246 and azacitidine (AZA) for the treatment of TP53 mutated Myelodysplastic Syndrome (MDS). No dose-limiting toxicities have been observed. Based on these encouraging data, Aprea intends to progress APR 246 into a Phase III study in the near future. The results presented at the ASH meeting is based on 20 patients with TP53 mutated MDS. The overall response rate was 95%, and 14 (70%) patients achieved a complete remission at data cutoff. These findings were accompanied by a deep molecular remission in the majority of patients as assessed by serial TP53 analysis. No dose-limiting toxicities have been experience

Karolinska Development's portfolio company Aprea Therapeutics presents continued positive results from a Phase Ib/II study of APR 2462.12.2018 18:00Pressmeddelande

STOCKHOLM, December 2, 2018. Karolinska Development's portfolio company Aprea Therapeutics today presented positive clinical results for its drug candidate APR 246 at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego, US. An Overall Response Rate of 95% and a Complete Remission (CR) rate of 70% were achieved in an ongoing Phase I/II combination study of APR 246 and azacitidine (AZA) for the treatment of TP53 mutated Myelodysplastic Syndrome (MDS). No dose-limiting toxicities have been observed. Based on these encouraging data, Aprea intends to progress APR 246 into a Phase III study in the near future. The results presented at the ASH meeting is based on 20 patients with TP53 mutated MDS. The overall response rate was 95%, and 14 (70%) patients achieved a complete remission at data cutoff. These findings were accompanied by a deep molecular remission in the majority of patients as assessed by serial TP53 analysis. No dose-limiting toxicities have been experience

Corline Biomedical AB: Patientrekrytering startar i Renaparin-studie30.11.2018 16:37Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att patientrekrytering i den kliniska fas 1-studien RENAPAIR-01 startar. I studien utvärderas bolagets läkemedelskandidat Renaparin® som är under utveckling för att förbättra utfallet av njurtransplantation. Patienter kommer inledningsvis att rekryteras på Akademiska sjukhuset i Uppsala. När de fyra första patienterna utvärderats inleds också rekrytering på Karolinska Universitetssjukhuset i Huddinge. Beskedet att patientrekrytering startar innebär att förberedelsearbetet inför studiestart är avslutat och att till exempel avtal, initieringsmöte, logistik, provhantering och monitorering är hanterat, samt att godkänt prövningsläkemedel nu finns tillgängligt för rekvirering av kirurgerna på transplantationskliniken i Uppsala för dosering till donatornjurar. När första patient doserats kommer detta meddelas separat. Corline har utvecklat och äger rättigheterna till Renaparin® som administreras direkt till den donerade njuren i

Stillfront: Bytro Labs lanserar en ny version av Supremacy 191427.11.2018 08:00Pressmeddelande

PRESSMEDDELANDE 2018-11-27 Bytro Labs, en studio inom Stillfront Group, lanserar en ny version av Supremacy 1914 Spelutvecklaren Bytro Labs, mest kända för sitt framgångsrika strategispel Call of War, har släppt en ny version av sin klassiska speltitel Supremacy 1914. Dagens lansering är den första av tre milstolpar för den nya versionen av Supremacy 1914 - The Great War som släpps 2019. Den första uppdateringen innehåller en komplett omarbetning av området för spelets community, ett nytt utseende för kartan samt ny 3D-teknologi. I nästa steg kommer Bytro Labs att gå vidare till "true cross platform" där spelet tillgängliggörs för fler plattformar, en strategi som tidigare har varit framgångsrik för titeln Call of War. Supremacy 1914 - The Great War släpps för Android senare i år och i början av 2019 släpps spelet för iOS och Steam. Det tredje och sista steget i lanseringen kommer i mitten av 2019 innehållande en större uppdatering avseende både innehåll och funktion, som färdigställer

Stillfront: Bytro Labs releases a new version of Supremacy 191427.11.2018 08:00Pressmeddelande

PRESS RELEASE November 27, 2018 Bytro Labs, part of Stillfront Group, releases a new version of Supremacy 1914 Online games developer Bytro Labs, best known for its grand strategy hit Call of War, has released a new version of their classic title Supremacy 1914. Today's release marks the first of three milestones for the new version Supremacy 1914 - The Great War in 2019. This first update features a completely reworked community area, a new map look and a new 3D rendering technology. In the next step Bytro Labs is further embracing its cross-platform strategy, which has already shown great success for Call of War. Supremacy 1914 - The Great War is releasing for Android phones later this year and is followed in early 2019 by iOS devices and leading PC gaming platform Steam. The third and final stage will be reached in mid-2019 with a major content and feature update, which will finalize Supremacy 1914 - The Great War and make the brand ready for the future ensuring its continued succes

Stillfront Group AB: eRepublik.com i mjuklansering för mobilen26.11.2018 12:26Pressmeddelande

PRESSMEDDELANDE 2018-11-26 eRepublik Labs, en studio inom Stillfront Group, mjuklanserar eRepublik.com för mobilen eRepublik.com firar 11 årsjubileum och lanseras för första gången mobilt. eRepublik Mobile finns tillgänglig som öppen beta version på Google Play early access program. Spelet förväntas befinna sig i mjuklansering i ett par månader. eRepublik.com är det första spelet som lanserades av eRepublik Labs 2007. Mer än tio miljoner människor har spelat spelet under dess elvaåriga historik. Spelet har som browser-version ett dedikerat community med mer än 35 000 månatliga unika spelare och intäkterna har stigit under året. eRepublik Mobile kommer att fungera i synkronisering med browser-versionen vilket betyder att både befintliga och nya spelare kommer att kunna spela på båda plattformarna nu. "eRepublik.com inledde vårt äventyr och var vårt största spel till dess att våra mobilspel, såsom War and Peace, lanserades. eRepublik är idag ett av våra fem huvudsakliga live-spel och tro

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum